Table 2.
Select reports of targeted therapy for extranodal NK/T cell lymphoma
| Target/therapy | Patients characteristics | Efficacy | Reference | |
|---|---|---|---|---|
| CD30 | Brentuximab vedotin | Refractory or relapsed HL or CD30(+) NHL patients | Modest efficacy. | [21] |
| A male with ENKTCL and CD30 expression | CR was achieved after four cycles of treatment. | [27] | ||
| Brentuximab vedotin and bendamustine | A woman with ENKTCL and CD30 expression | After two cycles of treatment, CR was achieved. | [28] | |
| Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) | Patients with CD30-positive peripheral T cell lymphomas | Significant improvement in progression-free survival and overall survival. | [28] | |
| BV with L-asparaginase and non-L-asparaginase | 26 patients with CD30+ PTCL | All patients (n = 26) achieved an objective response (CR rate, 88%; estimated 1-year PFS rate, 71%). | [14] | |
| CD38 | Daratumumab | A child with CD38+ recurrent B-ALL | Effective. | [36] |
| A patient with stage IV NKTCL | Patients reached a maximum sustained remission period of 21 weeks. | [37] | ||
| PD-1 | Nivolumab | 29 patients with recurrent or refractory lymphatic malignancies | A DBLCL patient and one with FL reached CR. | [48] |
| 3 patients with relapsed/refractory NKTCL | All patients achieved a clinical response. | [44] | ||
| Pembrolizumab | 7 patients with NKTCL | All patients achieved CRs. | [50] | |
| 7 patients with NKTCL | 2 patients reached CR and 2 reached PR. | [45] | ||
| 30 consecutive patients with relapsed/or refractory NHL | 7 patients reached CR and 7reached PR. | [51] | ||
| NF-κB | B-GIFOX (bortezomib, gemcitabine, oxaliplatin and ifosfamide) | 6 ENKTCL patients | The ORR was 42.8%. | - |
| Bortezomib, fludarabine and autologous haematopoietic stem cell transplantation | A patient with relapsed/refractory NKTCL | The patient remained disease-free as of March 2017. | [59] | |
| EBV antigens | Activated/stimulated T cells and LMP1/2- or LMP2-targeted strategies | 52 patients with EBV-related lymphoma | 11 patients with active disease reached CR, 2 patients achieved PR, and 5 ENKTCL patients reached CR. | [63] |
| 8 patients with localized disease and 2 advanced ENKTCL patients | All patients reached CR: OS and PFS were 100% and 90%, respectively. | [65] | ||
| CAR-T | CD19-CAR-T cells | 119 patients with B cell malignancies | Response rates (93%) were higher in all patients than in CLL patients (62%) and lymphoma patients (36%). | [66] |
| CD22-CAR-T cells | 34 patients with B-ALL | 24 patients achieved CR or CRI. | [70] | |
| CD28 co-stimulated anti-CD30 CAR-T cells | 7 patients with relapsed/refractory HL and 2 patients with ALCL | 2 patients with HL reached CR and 3 reached SD; 1 ALCL patients reached CR. | [67] | |
| 4-1BB co-stimulated anti-CD30 CAR-T cells | 17 HL patients and 1 cutaneous ALCL patients | 7 patients achieved PR and 6 patients achieved SD. | [68] |
EBV, Epstein-Barr virus; CR, complete response; PR, partial response; SD, stable disease; HL, Hodgkin’s lymphoma; ALCL, anaplastic large cell lymphoma; ENKTCL, extranodal NK/T cell lymphoma; PTCL, peripheral T cell lymphoma; OS, overall survival; PFS, progression-free survival; B-ALL, B cell acute lymphoblastic leukaemia.